PMID- 34779533
OWN - NLM
STAT- MEDLINE
DCOM- 20220401
LR  - 20220531
IS  - 1365-2230 (Electronic)
IS  - 0307-6938 (Linking)
VI  - 47
IP  - 4
DP  - 2022 Apr
TI  - The role of thalidomide in dermatology.
PG  - 667-674
LID - 10.1111/ced.15019 [doi]
AB  - Thalidomide is a medication that has been in existence for over half a century, 
      and has proven to be useful and effective in severe dermatological conditions. 
      For dermatologists, the ability of thalidomide to reduce the levels of the 
      cytokine tumour necrosis factor-alpha, along with its immunomodulatory and 
      anti-angiogenic properties, is of great significance, with the added advantage of 
      being an oral medication. Its use is of course strictly monitored, owing to its 
      potential adverse effects (AEs), particularly teratogenicity, with precautions 
      taken to ensure its safe and correct use by both prescriber and patient. In this 
      review, we look at the background and mechanism of action of thalidomide, provide 
      an overview of conditions it can be used for with case examples, explain the 
      potential AEs and monitoring requirements, and discuss future developments.
CI  - (c) 2021 British Association of Dermatologists.
FAU - Hussain, K
AU  - Hussain K
AUID- ORCID: 0000-0003-2116-7718
AD  - Department of Dermatology, Chelsea and Westminster Hospital NHS Foundation Trust, 
      London, UK.
FAU - Patel, P
AU  - Patel P
AUID- ORCID: 0000-0002-0446-9338
AD  - Department of Dermatology, Chelsea and Westminster Hospital NHS Foundation Trust, 
      London, UK.
FAU - Roberts, N
AU  - Roberts N
AD  - Department of Dermatology, Chelsea and Westminster Hospital NHS Foundation Trust, 
      London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211219
PL  - England
TA  - Clin Exp Dermatol
JT  - Clinical and experimental dermatology
JID - 7606847
RN  - 0 (Cytokines)
RN  - 4Z8R6ORS6L (Thalidomide)
SB  - IM
CIN - Clin Exp Dermatol. 2022 Apr;47(4):769-770. PMID: 34856016
CIN - Clin Exp Dermatol. 2022 May;47(5):982-983. PMID: 34997621
MH  - Cytokines
MH  - *Dermatology
MH  - Humans
MH  - *Thalidomide/adverse effects/therapeutic use
EDAT- 2021/11/16 06:00
MHDA- 2022/04/02 06:00
CRDT- 2021/11/15 08:57
PHST- 2021/11/09 00:00 [revised]
PHST- 2021/10/23 00:00 [received]
PHST- 2021/11/12 00:00 [accepted]
PHST- 2021/11/16 06:00 [pubmed]
PHST- 2022/04/02 06:00 [medline]
PHST- 2021/11/15 08:57 [entrez]
AID - 10.1111/ced.15019 [doi]
PST - ppublish
SO  - Clin Exp Dermatol. 2022 Apr;47(4):667-674. doi: 10.1111/ced.15019. Epub 2021 Dec 
      19.